ImmuPharma Selects Thermo Fisher CDMO for Kapiglucagon
ImmuPharma has named Thermo Fisher Scientific’s Patheon as the drug product CDMO for Kapiglucagon, following the earlier selection of Bachem for API manufacturing, as it pushes the glucagon prodrug toward IND-enabling development for Type 1 diabetes and potential dual-hormone artificial pancreas applications. The company is pursuing a streamlined regulatory path, potentially a 505(b)(2) in the U.S., with plans to file an IND and begin first-in-human studies subject to regulatory confirmation.
Business · 5 sources · Jul 22, 2026Read itThe journal
Open the journal →The conversation starts in the journal — be the first to post.
About Patheon
Patheon is a service brand within Thermo Fisher Scientific's brand portfolio. Contract development and manufacturing organization (CDMO) services offered under the Patheon brand include small molecule API, biologics, viral vectors, cGMP plasmids, formulation, clinical trials, logistics and commercial manufacturing and packaging. In 2017, Patheon was acquired by Thermo Fisher Scientific to form its Pharma Services business.
Everything about Patheon →- Headquarters
- Durham
- Inception
- 1974
- Website
- http://www.patheon.com/